Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1993 Nov;69(5):580–586. doi: 10.1136/adc.69.5.580

Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia.

K P Morris 1, J Sharp 1, S Watson 1, M G Coulthard 1
PMCID: PMC1029623  PMID: 8257180

Abstract

Recombinant human erythropoietin (r-HuEpo) is now available to correct the anaemia of end stage renal failure. The clinical consequences of increasing the haemoglobin concentration in children on dialysis are incompletely documented; a placebo controlled study is essential when assessing subjective changes, for example in appetite or other aspects of quality of life. A single blind, placebo controlled crossover study in 11 children with end stage renal failure was performed to assess the clinical benefits resulting from correction of anaemia. Ten of the 11 children completed 36 weeks of the study and seven completed both 24 week limbs. Subcutaneous administration of r-HuEpo twice a week resulted in an increase in haemoglobin concentration, from 73 to 112 g/l. This was associated with an objective improvement in exercise tolerance, and a subjective improvement in physical performance and health, and better school attendance. No consistent effect was seen on appetite, growth, psychosocial functioning, biochemical control, or peritoneal dialysis efficiency. A small but clinically unimportant increase in systolic and diastolic blood pressure was seen in five children. One child on antihypertensive treatment required an increase in dosage during r-HuEpo while another child required a reduction in treatment. These findings, together with the important cardiac benefits previously described during r-HuEpo treatment, support the use of r-HuEpo in all children with end stage renal failure and anaemia.

Full text

PDF
580

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacon C. J., Cranage J. D., Hierons A. M., Rawlins M. D., Webb J. K. Behavioural effects of phenobarbitone and phenytoin in small children. Arch Dis Child. 1981 Nov;56(11):836–840. doi: 10.1136/adc.56.11.836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bommer J., Alexiou C., Müller-Bühl U., Eifert J., Ritz E. Recombinant human erythropoietin therapy in haemodialysis patients--dose determination and clinical experience. Nephrol Dial Transplant. 1987;2(4):238–242. [PubMed] [Google Scholar]
  3. Bruce R. A., Kusumi F., Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J. 1973 Apr;85(4):546–562. doi: 10.1016/0002-8703(73)90502-4. [DOI] [PubMed] [Google Scholar]
  4. Campos A., Garin E. H. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO). Clin Pediatr (Phila) 1992 Feb;31(2):94–99. doi: 10.1177/000992289203100206. [DOI] [PubMed] [Google Scholar]
  5. Edmunds M. E., Walls J., Tucker B., Baker L. R., Tomson C. R., Ward M., Cunningham J., Moore R., Winearls C. G. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant. 1989;4(12):1065–1069. [PubMed] [Google Scholar]
  6. Evans J. H., Brocklebank J. T., Bowmer C. J., Ng P. C. Pharmacokinetics of recombinant human erythropoietin in children with renal failure. Nephrol Dial Transplant. 1991;6(10):709–714. doi: 10.1093/ndt/6.10.709. [DOI] [PubMed] [Google Scholar]
  7. Fabris F., Cordiano I., Randi M. L., Casonato A., Montini G., Zacchello G., Girolami A. Effect of human recombinant erythropoietin on bleeding time, platelet number and function in children with end-stage renal disease maintained by haemodialysis. Pediatr Nephrol. 1991 Mar;5(2):225–228. doi: 10.1007/BF01095958. [DOI] [PubMed] [Google Scholar]
  8. Hutchison A. J., Ofsthun N. J., Howarth D., Gokal R. The effect of hemoglobin concentration on peritoneal mass transfer and drain volumes in continuous ambulatory peritoneal dialysis. Perit Dial Int. 1992;12(2):230–233. [PubMed] [Google Scholar]
  9. Kampf D., Eckardt K. U., Fischer H. C., Schmalisch C., Ehmer B., Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron. 1992;61(4):393–398. doi: 10.1159/000186955. [DOI] [PubMed] [Google Scholar]
  10. Korbet S. M., Vonesh E. F., Firanek C. A. The effect of hematocrit on peritoneal transport. Am J Kidney Dis. 1991 Nov;18(5):573–578. doi: 10.1016/s0272-6386(12)80652-4. [DOI] [PubMed] [Google Scholar]
  11. Macdougall I. C., Davies M. E., Hutton R. D., Cavill I., Lewis N. P., Coles G. A., Williams J. D. The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant. 1990;5(11):950–955. doi: 10.1093/ndt/5.11.950. [DOI] [PubMed] [Google Scholar]
  12. Macdougall I. C., Roberts D. E., Neubert P., Dharmasena A. D., Coles G. A., Williams J. D. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet. 1989 Feb 25;1(8635):425–427. doi: 10.1016/s0140-6736(89)90014-7. [DOI] [PubMed] [Google Scholar]
  13. Montini G., Zacchello G., Baraldi E., Zanconato S., Suppiej A., Fabris F., Andreetta B., Pavanello L., Zacchello F. Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr. 1990 Oct;117(4):556–560. doi: 10.1016/s0022-3476(05)80688-2. [DOI] [PubMed] [Google Scholar]
  14. Morris K. P., Skinner J. R., Hunter S., Coulthard M. G. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure. Arch Dis Child. 1993 May;68(5):644–648. doi: 10.1136/adc.68.5.644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Navarro M., Alonso A., Avilla J. M., Espinosa L. Anemia of chronic renal failure: treatment with erythropoietin. Child Nephrol Urol. 1991;11(3):146–151. [PubMed] [Google Scholar]
  16. Rigden S. P., Montini G., Morris M., Clark K. G., Haycock G. B., Chantler C., Hill R. C. Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatr Nephrol. 1990 Nov;4(6):618–622. doi: 10.1007/BF00858637. [DOI] [PubMed] [Google Scholar]
  17. Scigalla P. Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. The European Multicenter Study Group. Contrib Nephrol. 1991;88:201–214. doi: 10.1159/000419530. [DOI] [PubMed] [Google Scholar]
  18. Sinai-Trieman L., Salusky I. B., Fine R. N. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr. 1989 Apr;114(4 Pt 1):550–554. doi: 10.1016/s0022-3476(89)80692-4. [DOI] [PubMed] [Google Scholar]
  19. Steinhauer H. B., Lubrich-Birkner I., Dreyling K. W., Hörl W. H., Schollmeyer P. Increased ultrafiltration after erythropoietin-induced correction of renal anemia in patients on continuous ambulatory peritoneal dialysis. Nephron. 1989;53(1):91–92. doi: 10.1159/000185716. [DOI] [PubMed] [Google Scholar]
  20. Tomson C. R., Feehally J., Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 1992;7(2):129–132. doi: 10.1093/oxfordjournals.ndt.a092082. [DOI] [PubMed] [Google Scholar]
  21. Upton C. J., Tyrrell J. C., Hiller E. J. Two minute walking distance in cystic fibrosis. Arch Dis Child. 1988 Dec;63(12):1444–1448. doi: 10.1136/adc.63.12.1444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Warady B. A., Sabath R. J., Smith C. A., Alon U., Hellerstein S. Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol. 1991 Nov;5(6):718–723. doi: 10.1007/BF00857883. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES